Aomei Medical

Aomei Medical Products Joint-stock Co., Ltd. (hereinafter referred to as "Aomei Medical" or "the Company") was founded in Hong Kong in 1997 and listed on the Shenzhen Stock Exchange in March 2019 (002950.SZ). Focusing on the R&D, production, and sales of disposable medical dressings, instruments, and hygiene products, after 22 years of development, Aomei Medical has completed full industry chain coverage from spinning, weaving, bleaching, to processing, packaging, sterilization, and testing, with outstanding advantages in automation and large-scale production, and is a leading manufacturer and exporter of medical dressings.
The company has over 5,000 employees, 3 core production bases, over 400,000 square meters of modern industrial plants, dozens of advanced automated and intelligent production lines, and over 100 invention patents and utility model patents. The company's products are used in fields such as infection isolation and protection, wound bandaging and care, and various surgeries, with some products applied in high-precision fields like neurosurgery. Products are mainly for export, sold to Europe, America, Asia-Pacific, the Middle East, and other regions, with major well-known customers including international medical device manufacturers such as Medline, Dukal, Paul Hartmann, and Medicom. In 2017, the company was selected as a pilot enterprise for the integration of informatization and industrialization management system by the Ministry of Industry and Information Technology. Since 2008, the company has maintained the first place in China's medical dressing industry for exports for 12 consecutive years.
With the mission of "Focusing on medical and health business, making Aomei products the best choice for global consumers," the company practices the vision of "being the pioneer of healthy life and the creator of quality life." During the pandemic, as a key production enterprise for medical protective supplies designated by Hubei Province, the company stepped forward at the first moment, resumed work and increased production, overcame difficulties, and completed the mission of "anti-epidemic supply guarantee" with quality, quantity, and price assurance, while also undertaking the central reserve tasks for epidemic prevention materials, Hubei Province reserve tasks, and foreign aid tasks. In the future, the company will continue to deepen its professional fields in existing medical devices, strongly expand the infection protection field, and explore consumer market areas; continue to expand international market competitive advantages and actively develop the domestic market. At the same time, the company will fully leverage its experience in high-end medical textiles to develop more comfortable and safe care products and daily necessities for Chinese consumers, aiming to "motivate employee value, create enterprise value, realize customer value," and achieve healthy, efficient, and sustainable development. Meet needs, do better, We Care, We Can.